Did China cure diabetes? What the stem-cell studies actually show
Short answer: no. Research teams in China have reported promising results from experimental islet-cell transplants in small numbers of patients. These findings are not a widely available cure, and access for international patients is not established.
Evidence firstType 1 & Type 2 distinguishedNo guaranteed trial access
ParkMega helps clarify pathways and documentation. It does not provide medical diagnosis, promise trial enrollment or guarantee treatment.
First, understand the difference
“Stem-cell therapy” can mean fundamentally different procedures. A published case report, a registered trial and a clinic advertising infusions are not interchangeable.
Established treatment
Everyday diabetes care
Insulin, glucose monitoring, medicines, complication screening and specialist follow-up remain the foundation of care.
Investigational
Islet-cell replacement
Researchers are testing transplanted insulin-producing cells, including stem-cell-derived islets. Immune rejection and safety remain major challenges.
Verify carefully
Commercial “stem-cell packages”
Promotional offers are not proof of efficacy, regulatory authorisation or a clinical-trial place. Ask for the precise intervention and supporting evidence.
What happened in China? Three research reports
These are selected reports discussed in the existing ParkMega research review, not a list of treatments available for booking.
Tianjin / CiPSC islets
A published first-in-human case described insulin independence following an experimental transplant in one patient already receiving immunosuppression. A single case does not establish a general cure.
Shanghai Changzheng
A published single-patient report described islet-cell transplantation in long-standing Type 2 diabetes. The patient’s circumstances and prior treatment limit generalisation.
Shanghai E-islet series
A small report described different outcomes across three people. Immune suppression and graft function are central to interpreting the results; it is not evidence of an established cure.
Study-specific protocol and eligibility need independent verification before any patient inquiry.
Key distinction: insulin independence observed in selected experimental cases is not the same as a durable, safe, widely available cure.
Clinical evidence: what the cases actually showed
One patient, already immunosuppressed
An experimental autologous CiPSC-derived islet transplant was followed by insulin independence beginning around day 75. This was one first-in-human case; the recipient was already on immunosuppression.
Cell study, PMID 39326417 · ChiCTR2300072200
One recipient with a kidney-transplant history
The published patient was already in an immunosuppressed transplant setting. Insulin was discontinued after experimental E-islet transplantation. These circumstances limit generalisation to other people with Type 2 diabetes.
Cell Discovery, PMID 38684699 · NCT05294822
Type 1 · Shanghai · 2026
Three recipients, mixed outcomes
One adult: prolonged insulin independence while receiving immunosuppression.
Another recipient: graft function was lost after immunosuppression was discontinued.
Adolescent: improvement, but insulin was still required.
Shi et al., Lancet Diabetes & Endocrinology 2026. DOI 10.1016/S2213-8587(25)00423-1.
A published case or three-patient series does not establish a safe, broadly available cure. These protocols are not confirmed as bookable international-patient treatments.
Why replacing cells is not enough
Type 1 diabetes
The immune system destroys beta cells. Even if replacement cells produce insulin, recurrent autoimmunity or transplant rejection can threaten their survival. Immunosuppression and immune-protection approaches have trade-offs.
Type 2 diabetes
Insulin resistance and changes in insulin production interact. Evidence for a cell-transplant procedure in one patient does not mean the approach is suitable for the broader Type 2 population.
Learn more: Type 1 diabetes treatment · Type 2 diabetes treatment · Type 1 diabetes research in 2026
Four different routes often called “stem-cell treatment”
Stem-cell-derived islets
Investigational insulin-producing cell replacement with transplant and immune-protection challenges.
Mesenchymal-cell infusions
Different products and evidence. Commercial infusion offers cannot be equated with published islet transplant studies.
Special-zone programme
Hainan Boao Lecheng uses programme-specific authorisations; it is not nationwide approval or a registered trial by default.
Established endocrinology care
Insulin, medication, monitoring, specialist review and complication management. These should not be presented as an experimental cure.
Never stop or change prescribed insulin on the basis of news headlines or a commercial offer. Discuss care with your treating clinician.
Can an international patient access these studies?
Do not assume availability. A registry listing is not evidence that a study is recruiting foreign patients or that the reported treatment can be purchased.
Identify the exact protocol
Find the hospital, investigator, intervention name and study registration number.
Check current status
Confirm enrollment, eligibility, study location and international-patient rules with the team responsible.
Clarify the route before travel
Request written confirmation of whether a screening review is possible and what records are required.
China research registrations worth checking
These were identified in ParkMega’s previous research. Current recruitment and eligibility for non-Chinese patients have not been confirmed. Registration does not mean treatment can be booked.
| Registration | Research setting |
|---|---|
| NCT06731218 | RGB-5088 islet-cell research · Tianjin |
| NCT07528105 | Investigational anti-CD7 CAR-T · Shanghai |
| NCT07495956 | Cell-therapy research · Shenzhen |
| NCT01996228 | Stem Cell Educator, children with Type 1 · Changsha |
| NCT01413035 | MSC research in Type 2 · Jinan |
| NCT07503028 | Investigational iPSC-derived pancreatic islets · Hefei |
Chinese Clinical Trial Registry entry ChiCTR2600130840 concerns adipose-derived mesenchymal-cell research in Type 2 diabetes, not the E-islet cases. Verify study status, investigators, follow-up and international eligibility directly with the study site.
What does stem-cell treatment cost in China?
There is no single fixed 2026 price. Publicly advertised packages may quote USD 12,000–25,000, but advertising prices are not proof of efficacy, hospital acceptance or a complete clinical bill. The cost of a registered clinical trial is a different question.
Questions to ask before paying
| Check | What to request in writing |
|---|---|
| Hospital and medical team | Legal provider name, named investigator or physician, and location |
| Product and procedure | Cell source, manufacturing, protocol, administration route and authorisation status |
| Expected outcomes | Peer-reviewed evidence for your specific condition, not testimonials |
| Full cost | Tests, admission, medication, monitoring, travel and possible complications |
Related: Diabetes treatment costs in China and how to evaluate a “cure in China” headline.
Initial inquiry · No medical documents required
Find out which route is realistic for you
Ask ParkMega about established diabetes care, the status of a specific clinical study, or whether a hospital can review a case. Initial contact does not guarantee an offer or eligibility.
Do not include diagnosis, laboratory results or medical reports in the first WhatsApp message. Ask how sensitive documents can be shared securely.
Choose what you need next
Frequently asked questions
Has China cured Type 1 diabetes?
No. Early reports of insulin independence in selected experimental transplant recipients are not proof of a widely available or durable cure. Immune protection, safety, and long-term outcomes remain challenges.
Can I buy the transplant used in a published study?
Not based on a publication alone. Availability depends on the exact study protocol, responsible hospital, current recruitment and regulatory arrangements.
Are commercial stem-cell infusions the same as stem-cell-derived islets?
No. Cell types, preparation methods, delivery routes and scientific evidence may be very different. Ask the provider for the intervention name and published data.
What should I send ParkMega first?
Start with a general inquiry and the type of assistance needed. Discuss consent, privacy and a secure transfer method before sharing clinical records.
Evidence, verification and editorial notes
Research summaries require regular review as trial status and clinical results change. The linked evidence below helps distinguish experimental interventions from routine care.
- Cell (2024): autologous CiPSC-derived islet transplantation case
- Cell Discovery (2024): islet replacement in Type 2 diabetes
- Diabetes UK: Is there a cure for diabetes?
- Diabetes UK: Beta-cell therapy
- ClinicalTrials.gov: verify recruitment and eligibility
ParkMega is a patient-coordination service, not a clinical trial sponsor or a provider of experimental treatments. Clinical claims should be reviewed by qualified professionals. Last editorial design pass: November 2026.
Check a stem-cell offer or research route
Send the diagnosis and records you already have before a route is suggested. Published research, a registered trial, and a commercial package are different. This is not a cure and not a booking.